We have updated our privacy policy. If you have any question, contact us at privacy@scicrunch.org. Dismiss and don't show again

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome.

Patients with Marfan syndrome (MFS), a multisystem disorder caused by mutations in the gene encoding the extracellular matrix (ECM) protein fibrillin 1, are unusually vulnerable to stress-induced cardiac dysfunction. The prevailing view is that MFS-associated cardiac dysfunction is the result of aortic and/or valvular disease. Here, we determined that dilated cardiomyopathy (DCM) in fibrillin 1-deficient mice is a primary manifestation resulting from ECM-induced abnormal mechanosignaling by cardiomyocytes. MFS mice displayed spontaneous emergence of an enlarged and dysfunctional heart, altered physical properties of myocardial tissue, and biochemical evidence of chronic mechanical stress, including increased angiotensin II type I receptor (AT1R) signaling and abated focal adhesion kinase (FAK) activity. Partial fibrillin 1 gene inactivation in cardiomyocytes was sufficient to precipitate DCM in otherwise phenotypically normal mice. Consistent with abnormal mechanosignaling, normal cardiac size and function were restored in MFS mice treated with an AT1R antagonist and in MFS mice lacking AT1R or β-arrestin 2, but not in MFS mice treated with an angiotensin-converting enzyme inhibitor or lacking angiotensinogen. Conversely, DCM associated with abnormal AT1R and FAK signaling was the sole abnormality in mice that were haploinsufficient for both fibrillin 1 and β1 integrin. Collectively, these findings implicate fibrillin 1 in the physiological adaptation of cardiac muscle to elevated workload.

Pubmed ID: 24531548 RIS Download

Mesh terms: Adult | Angiotensin II Type 1 Receptor Blockers | Animals | Cardiomyopathy, Dilated | Child | Cross-Sectional Studies | Extracellular Matrix | Fibrillin-1 | Fibrillins | Focal Adhesion Kinase 1 | Humans | Losartan | MAP Kinase Signaling System | Male | Marfan Syndrome | Mechanotransduction, Cellular | Mice | Mice, Transgenic | Microfilament Proteins | Myocardium | Myocytes, Cardiac | Organ Size | Receptor, Angiotensin, Type 1

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: PHS HHS, Id: HHSN268200648199C
  • Agency: NHLBI NIH HHS, Id: T32 HL007824
  • Agency: NIDDK NIH HHS, Id: R01 DK036425
  • Agency: PHS HHS, Id: HHSN268201000048C
  • Agency: NIGMS NIH HHS, Id: P30 GM103341
  • Agency: NHLBI NIH HHS, Id: HHSN268201000048C

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.